Havana, Cuba, Mar 2.- A new Cuban vaccine against chronic Hepatitis B (Nasvac) will be one of the innovations to be introduced during the upcoming International Congress on Biotechnology scheduled for March 5-8 in Havana.
Dr. Gerardo Guillen Nieto, vice president of the event’s organizing committee, told reporters that good results have been obtained during the almost finished clinical studies of this vaccine, which is unique in the world.
Guillen Nieto, head of Biomedical Research at the Havana-based Center of Genetic Engineering and Biotechnology (CIGB), said the results obtained during clinical studies of the vaccine in Cuba and Bangladesh are far superior than any others involving the treatment of Hepatitis B.
More than 600 specialists from almost 40 countries will participate in the International Congress on
Biotechnology. The list of guests includes American biologist Peter Agre, the 2003 Nobel Prize in Chemistry and professor at the Johns Hopkins University, who will give a lecture on biochemical and biotechnological advances and their impact on the treatment of malaria.
During the event, Cuban specialists will also introduce the results of clinical trials of another therapeutic vaccine against Hepatitis C developed in the Caribbean nation.
Also scheduled are three symposiums on the research and development of products and vaccines against cancer, dengue, AIDS, and Hepatitis B and C, among other diseases.
More than 70 foreign and 30 Cuban lecturers will speak about the topics that include pre-clinical trials of a vaccine candidate against HIV/AIDS, whose first phase of clinical trials should begin this year, according to Guillen Nieto. (ACN)